Clinical trial
A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.
NCT01323244 is registered in ClinicalTrials.gov with Janssen R&D Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.
- Lead sponsor
- Janssen R&D Ireland
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- March 31, 2015
- Enrollment
- 142 (actual)
- Sites
- 72
Conditions
As the registry lists them; a condition with its own page is linked.